Predicted expression of genes involved in the thiopurine metabolic pathway and azathioprine discontinuation due to myelotoxicity
Sign Up to like & getrecommendations! Published in 2022 at "Clinical and Translational Science"
DOI: 10.1111/cts.13243
Abstract: TPMT and NUDT15 variants explain less than 25% of azathioprine‐associated myelotoxicity. There are 25 additional genes in the thiopurine pathway that could also contribute to azathioprine myelotoxicity. We hypothesized that among TPMT and NUDT15 normal… read more here.
Keywords: azathioprine discontinuation; tpmt nudt15; myelotoxicity; due myelotoxicity ... See more keywords
Race, Genotype, and Azathioprine Discontinuation
Sign Up to like & getrecommendations! Published in 2022 at "Annals of Internal Medicine"
DOI: 10.7326/m21-4675
Abstract: BACKGROUND Thiopurines are an important class of immunosuppressants despite their risk for hematopoietic toxicity and narrow therapeutic indices. Benign neutropenia related to an ACKR1 variant (rs2814778-CC) is common among persons of African ancestries. OBJECTIVE To… read more here.
Keywords: race; azathioprine discontinuation; genotype; hematopoietic toxicity ... See more keywords
Beyond Race: A Wake-up Call for Drug Therapy Informed by Genotyping
Sign Up to like & getrecommendations! Published in 2022 at "Annals of Internal Medicine"
DOI: 10.7326/m22-1827
Abstract: People can vary substantially in their response to drugs. Genomic variation accounts for an estimated 20% to 95% of therapeutic effects. The purpose of pharmacogenetics is to understand how genetic variation affects treatment outcomes, with… read more here.
Keywords: race; azathioprine discontinuation; drug; ancestry ... See more keywords